Cargando…

2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study

BACKGROUND: Central line-associated bloodstream infections (CLABSI) are a known complication of central venous access. Pulmonary artery catheters (PAC) are frequently used in status 1A pre-heart transplant patients, at the top of the heart transplant waiting list. These patients often have a PAC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yetmar, Zachary, Lahr, Brian, O’Horo, John, Behfar, Atta, Sampathkumar, Priya, Beam, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254604/
http://dx.doi.org/10.1093/ofid/ofy210.1750
_version_ 1783373758367531008
author Yetmar, Zachary
Lahr, Brian
O’Horo, John
Behfar, Atta
Sampathkumar, Priya
Beam, Elena
author_facet Yetmar, Zachary
Lahr, Brian
O’Horo, John
Behfar, Atta
Sampathkumar, Priya
Beam, Elena
author_sort Yetmar, Zachary
collection PubMed
description BACKGROUND: Central line-associated bloodstream infections (CLABSI) are a known complication of central venous access. Pulmonary artery catheters (PAC) are frequently used in status 1A pre-heart transplant patients, at the top of the heart transplant waiting list. These patients often have a PAC in place for extended periods of time and are thus at risk for CLABSI. Our institution’s practice includes routine PAC exchange after 21 days of use. We sought to estimate the risk of CLABSI and determine whether factors influenced infection rate. METHODS: We conducted a retrospective, descriptive study from January 2013 to December 2016 identifying characteristics of PAC use and infection rate in adult status 1A pre-heart transplant patients. Time to CLABSI was analyzed with Kaplan–Meier estimates. The effect of CLABSI on time to transplant and death were analyzed in time-dependent Cox models. RESULTS: We identified 61 status 1A pre-heart transplant patients with PACs during this time period with 219 PACs and 2566 line-days. Median duration of PAC was 11 days. There were 14 CLABSIs for an infection rate of 5.46/1,000 line-days (95% CI: 2.98–9.15), compared with 1.06/1,000 line-days for our institution’s intensive care unit rate. Causative organisms were coagulase-negative Staphylococcus (79%), Enterobacter (7%), E. coli (7%), and Klebsiella (7%). There was a trend toward higher infection rate per 1,000 line-days with longer duration of PACs. Lines in place for 0–10 days resulted in an infection rate of 3.14 (1.02–7.32); 11–20 days with a rate of 8.70 (3.19–18.94); and >20 days with a rate of 32.61 (6.72–95.30). There was a trend toward higher infection rate with more concomitant non-PAC lines used (0 other lines, 4.57; 1 line, 6.21; 2 or more, 11.56). Median time to infection diagnosis from PAC placement was 29 days (23–49). Line infection was associated with shorter time to transplant (hazard ratio 2.49; P = 0.027), but no effect on mortality (hazard ratio 1.79; P = 0.355). CONCLUSION: Our study demonstrated a high rate of CLABSI with PAC, with a trend toward increased risk with longer use, and presence of concomitant lines. Infection was associated with a shorter time to transplant, though not with time to death. Prolonged PAC use in the status 1A population should be revisited. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254604
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62546042018-11-28 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study Yetmar, Zachary Lahr, Brian O’Horo, John Behfar, Atta Sampathkumar, Priya Beam, Elena Open Forum Infect Dis Abstracts BACKGROUND: Central line-associated bloodstream infections (CLABSI) are a known complication of central venous access. Pulmonary artery catheters (PAC) are frequently used in status 1A pre-heart transplant patients, at the top of the heart transplant waiting list. These patients often have a PAC in place for extended periods of time and are thus at risk for CLABSI. Our institution’s practice includes routine PAC exchange after 21 days of use. We sought to estimate the risk of CLABSI and determine whether factors influenced infection rate. METHODS: We conducted a retrospective, descriptive study from January 2013 to December 2016 identifying characteristics of PAC use and infection rate in adult status 1A pre-heart transplant patients. Time to CLABSI was analyzed with Kaplan–Meier estimates. The effect of CLABSI on time to transplant and death were analyzed in time-dependent Cox models. RESULTS: We identified 61 status 1A pre-heart transplant patients with PACs during this time period with 219 PACs and 2566 line-days. Median duration of PAC was 11 days. There were 14 CLABSIs for an infection rate of 5.46/1,000 line-days (95% CI: 2.98–9.15), compared with 1.06/1,000 line-days for our institution’s intensive care unit rate. Causative organisms were coagulase-negative Staphylococcus (79%), Enterobacter (7%), E. coli (7%), and Klebsiella (7%). There was a trend toward higher infection rate per 1,000 line-days with longer duration of PACs. Lines in place for 0–10 days resulted in an infection rate of 3.14 (1.02–7.32); 11–20 days with a rate of 8.70 (3.19–18.94); and >20 days with a rate of 32.61 (6.72–95.30). There was a trend toward higher infection rate with more concomitant non-PAC lines used (0 other lines, 4.57; 1 line, 6.21; 2 or more, 11.56). Median time to infection diagnosis from PAC placement was 29 days (23–49). Line infection was associated with shorter time to transplant (hazard ratio 2.49; P = 0.027), but no effect on mortality (hazard ratio 1.79; P = 0.355). CONCLUSION: Our study demonstrated a high rate of CLABSI with PAC, with a trend toward increased risk with longer use, and presence of concomitant lines. Infection was associated with a shorter time to transplant, though not with time to death. Prolonged PAC use in the status 1A population should be revisited. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254604/ http://dx.doi.org/10.1093/ofid/ofy210.1750 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Yetmar, Zachary
Lahr, Brian
O’Horo, John
Behfar, Atta
Sampathkumar, Priya
Beam, Elena
2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title_full 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title_fullStr 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title_full_unstemmed 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title_short 2094. Pulmonary Artery Catheter Epidemiology of Risk (PACER) Study
title_sort 2094. pulmonary artery catheter epidemiology of risk (pacer) study
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254604/
http://dx.doi.org/10.1093/ofid/ofy210.1750
work_keys_str_mv AT yetmarzachary 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy
AT lahrbrian 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy
AT ohorojohn 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy
AT behfaratta 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy
AT sampathkumarpriya 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy
AT beamelena 2094pulmonaryarterycatheterepidemiologyofriskpacerstudy